Objective: Drug-eluting stents (DES) have considerably reduced the rates of in-stent restenosis (ISR). Several studies reported pre-procedural C-reactive protein (CRP), neutrophil to lymphocyte (N/L) ratio, red cell distribution width (RDW), serum uric acid (UA), and mean platelet volume (MPV) as independent predictors of ISR using bare metal stents. This study investigates whether any laboratory parameter obtained before the coronary stenting procedure is associated with ISR using DES in stable coronary artery disease.
I n-stent restenosis (ISR) is a significant problem, affecting up to 30% of patients in the era of baremetal stents (BMS). [1] Stent implantation causes injury in the coronary vessel endothelium, initiating both local and systemic inflammatory responses, which play an important role in the pathophysiology of ISR. [2, 3] Patient-dependent factors, clinical conditions in which the patient undergoes the procedure, technical details, and characteristics of the lesion constitute the spectrum of variables which lead to ISR. Drug-eluting stents (DES) have improved outcomes by reducing neointimal hyperplasia, thus reducing the rate of ISR to less then 10% [4, 5] and reducing repeat revascularization procedures. [6] Several studies investigated whether laboratory parameters measured by complete blood count or biochemical analysis before the coronary stenting procedure could predict ISR. Red cell distribution width (RDW), [7] neutrophil to lymphocyte (N/L) ratio, [8] mean platelet volume (MPV), [9] serum uric acid levels (UA), [10] and serum C-reactive protein levels (CRP) [11] were found to be associated with ISR. Most of these studies were performed using BMS.
The purpose of this study was to investigate whether any readily-available parameter measured by a simple blood draw before the coronary stenting procedure could be associated with in-stent restenosis using drug-eluting stents in patients admitted with stable coronary artery disease (CAD).
METHODS
This is a retrospective study analysing the hospital records of patients with stable angina pectoris or angina equivalent symptoms who were admitted to the cardiology outpatient clinic of a university hospital and decided to undergo coronary angiography and elective stenting after appropriate non-invasive tests were performed. Inclusion criteria included age (range: (routine control  angiography performed 6 months -1 year after stenting, is the standard practice in our institution).
Exclusion criteria consisted of history of coronary artery by-pass graft operation, left-main lesion, chronic total occlusion, BMS or first generation DES, in-stent restenosis, acute or chronic infection during the initial procedure, malignancy, anemia, recent blood transfusion, renal insufficiency, hepatic insufficiency, hypo-or hyperthyroidism, and any rheumatologic, immunologic or inflammatory disorders. In addition, patients who received polymer-free DES were excluded because the polymer-free structure could possess different properties with respect to in-stent restenosis than the polymer-based stents used in this study, which sought to avoid a heterogeneous study population with respect to the nature of the stents implanted.
All percutaneous coronary intervention procedures with stenting performed between January 2012 and April 2014 were consecutively analysed in terms of inclusion and exclusion criteria, after which 315 eligible patients were enrolled to the study. This study was conducted according to the recommendations of the Declaration of Helsinki on Biomedical Research involving human subjects and was approved by the institutional ethics committee.
All coronary stenting procedures were performed through femoral artery by standard techniques with 7 Fr guiding catheters using GE Innova 4100 cath laboratory (GE Healthcare, Milwaukee, WI, USA Unfractionated heparin 100 U/kg was administered at the beginning of the procedure to maintain activated clotting time >250 seconds. Choice of stent, predilatation or postdilatation of the stent, and use of glycoprotein IIb/IIIa inhibitors were determined by the operator. Successful PCI was defined as TIMI grade III flow without any major complications with a residual stenosis <20% by visual estimation. All patients were prescribed ASA 100 mg indefinitely and clopidogrel 75 mg for ≥1 year. Stent restenosis was concluded according to the QCA analysis of the control coronary angiography and defined as >50% narrowing in a vessel including 5 mm proximal and distal to the stent edge. Restenosis pattern was defined as focal when the luminal narrowing was <10 mm in length, and diffuse when it was ≥10 mm in length. The data was analysed by two cardiologists, with a third cardiologist consulted in the case of discrepancy.
Clinical and demographic data of patients-including age, presence of hypertension, diabetes, hyperlipidemia, and smoking status-were noted from the hospital records. All laboratory data at the time of initial stenting procedure were also recorded. Laboratory data, which was measured by immunoturbidimetric assay (Abbott Architect c8000, USA), consisted of complete blood count (Cell-Dyn 3700, Abbott, USA) and biochemistry (Unicel Dx C800 Synchron, Beckman Coulter, USA), including kidney function tests, hepatic function tests, serum UA levels, lipid profile and CRP. These data were obtained from venous blood samples which were drawn upon 12 hours of fasting before the coronary stent implantation.
Statistical analyses
Statistical analyses were performed using SPSS statistical software (IBM SPSS Statistics 21). ShapiroWilk test was performed for distribution pattern. Categorical variables were expressed as percentages, whereas continuous variables were presented as mean±standard deviation. Continuous variables were compared by Student's t-test and Mann-Whitney U tests. χ 2 test was used for the categorical variables between the two groups. Univariate and multivariate regression analysis was performed in order to identify the determinants of ISR. All tests of significance were two-tailed. Statistical significance was defined as p<0.05. Table 1 shows basal characteristics of the study population. Mean age was 65.3±10.5, and 65% of the patients were male. Rate of diabetics was 41.9%. According to ACC/AHA lesion classification, 49.5% of the lesions were of type B, whereas 40.3% were of type C. Restenosis rate was 10.2%. tical significance. There were no significant differences between the two groups with respect to N/L ratio, monocyte count, eosinophil count, RDW, MPV, and total bilirubin levels ( Table 2) . Table 3 demonstrates the angiographic parameters obtained by QCA related to the coronary lesion and When analysed with respect to the presence of ISR, the ISR group contained more patients who were diabetic and smokers than in the non-ISR group. Serum creatinin and CRP levels were significantly higher in the ISR group. Serum uric acid levels were 5.7±1.4 and 5.3±1.3 in the ISR and non-ISR groups, respectively; however, this result did not reach statis- Mean stent length and number of stents implanted per lesion were higher in the ISR group, whereas mean stent diameter was lower. When QCA data were compared, pre-procedural and post-procedural mean RVD and MLD were lower in the ISR group, while pre-procedural and post-procedural percentages of diameter stenosis were higher in the ISR group. Table 4 shows the results of logistic regression analysis. In the univariate regression analysis (Table  4) , DM, serum CRP levels, stent length, stent diameter, pre-PCI diameter stenosis, pre-PCI MLD, post-PCI diameter stenosis (residual stenosis), post-PCI RVD, and post-PCI MLD were predictors of ISR. Nonetheless, multivariate regression analysis identified only DM and post-PCI diameter stenosis (residual stenosis) as independent predictors of ISR (Table 5) .
RESULTS

DISCUSSION
We analysed whether any routinely measured hematologic or biochemical parameter might be used as a predictor of ISR in stable CAD in the era of 2 nd generation DES. Serum CRP level was identified as an ISR predictor in the univariate regression analysis. However, multivariate regression analysis revealed that only the presence of DM and post-PCI residual stenosis were significant predictors of ISR using 2 nd generation DES in stable patients.
In this study, we detected an overall restenosis rate of 10.2%. This is a slightly high rate considering the use of DES; nevertheless, had we restricted coronary angiography procedures only to symptomatic patients, a lower restenosis rate may have been reported. Routine coronary angiography after 6-8 months of stent restenosis remains controversial. In the 2012 appropriate use criteria for diagnostic coronary angiog- Th1 lymphocytes primarily result from classical inflammatory response; however, eosinophils and Th2 lymphocytes result from allergic inflammation, which is a pathogenetic mechanism in DES but not BMS. [1] Hypersensitivity reactions to the polymer employed in DES underlie allergic inflammation. Although blood eosinophil or monocyte count does not reflect the amount of inflammatory infiltrate in the stented segment, we nonetheless compared their levels between ISR and non-ISR patients. No significant differences were found.
In BMS restenosis, the main process is neointimal proliferation. This is characterized by smooth muscle cell proliferation and extracellular matrix synthesis, which are driven by arterial inflammation caused by the medial damage and/or penetration of the stent struts into the lipid core of atherosclerotic plaques. [16] Intimal hyperplasia after BMS usually peaks between 6 months-1 year, after which a quiescent period resumes. [17, 18] The mechanism for DES restenosis includes different aspects. Chronic inflammation and impaired endothelial function cause late de novo neoraphy, routine control angiography after stenting was considered unnecessary, unless there were symptoms or signs of ischemia. [12] However, in a recently published study conducted on a large cohort of 10,004 patients, presence of restenosis at follow-up angiography predicted 4-year mortality, and prognostic value was maintained in asymptomatic patients as well as symptomatic patients. [13] In a retrospective study of 624 patients who had undergone PCI with BMS due to stable or unstable angina pectoris, pre-procedural N/L ratio was a strong and independent predictor of restenosis. [8] Serum UA, which is associated with atherosclerosis as a result of proinflammatory properties, was also found to be a strong predictor of ISR in BMS in patients with stable and unstable pectoris. [10] CRP is a well-studied marker of systemic inflammation and was found to be related to atherosclerotic events. [14] It was shown to be a significant predictor of angiographic BMS restenosis in a meta-analysis including 2,747 patients. [15] Inflammation is undoubtedly an important pathogenetic mechanism of stent restenosis. Monocytes, neutrophils, and [24] and late de novo neoatherosclerosis. [19] Long-term prospective studies performing control coronary angiography-preferably with IVUS-and obtaining serial measurements of all hematologic, biochemical and inflammatory markers of interest would be beneficial in determining whether these parameters are significant predictors of ISR in DES.
In conclusion, in stable CAD when 2 nd generation DES was used, patient-related factors and procedural factors were of paramount importance. None of the pre-procedural blood parameters could be safely used to predict future ISR. atherosclerosis in both BMS and DES; however, this occurs earlier and with greater frequency in DES. [19] Hypersensitivity reaction to the employed polymer is another pathogenetic mechanism of ISR in DES.
Elevated CRP levels were associated with stent thrombosis, death, myocardial infarction, and stroke in patients receiving DES. [20, 21] Although pre-procedural CRP was an independent predictor of adverse cardiac events, it was not detected as a predictor of stent restenosis with DES. Park et al. showed that while event-free survival was decreased in patients with higher pre-procedural CRP levels who received DES, restenosis rates were not significantly different in the lowest and highest tertiles of CRP. [22] In addition, pre-procedural CRP was not correlated with the degree of diameter stenosis, MLD, or late lumen loss at follow up. In light of these findings, it can be supposed that the association between CRP and adverse events reported in those studies may be attributed to stent thrombosis rather than stent restenosis, considering that higher inflammatory activity is associated with increased platelet and clotting cascade activity. [23] In our study, CRP levels were higher in patients with ISR, and it was a predictor of ISR in univariate but not multivariate regression analysis.
Studies describing associations between serum CRP, N/L ratio, serum UA levels, MPV, and RDW are typically performed with BMS. We have not detected any differences with respect to N/L ratio or serum UA levels in patients with or without ISR. This discrepancy is probably due to the difference between the study designs. Our study population consisted of patients only with stable CAD, and we used 2 nd generation DES. Anti-proliferative and anti-inflammatory effects of the drugs might have prevented us from detecting any inflammatory marker as a predictor of DES ISR.
Kurtul et al. reported that RDW predicted ISR in BMS stable CAD patients. [7] They concluded that immaturation of red blood cells from inflammatory cytokines which cause heterogeneity in RBC size, and oxidative stress which also causes heterogeneity in RBC size were the factors which raised RDW as a predictor of ISR. However, our results differed from that study, as we found similar RDW levels in both ISR and non-ISR patients.
The main limitation of the study was the retrospective design, which prevented us from inferring causal-
